WALTHAM,
Mass., Oct. 31, 2023 /PRNewswire/ -- Fresenius
Medical Care, the world's leading provider of products and services
for individuals with renal diseases, has appointed Craig Cordola (52) as new Management Board
member for the globally operating Care Delivery segment. Cordola
will start on January 1, 2024, as
Chief Executive Officer of Care Delivery. He will be based in
Waltham, Massachusetts.

Craig Cordola will succeed
William (Bill) Valle (63) as part of
a planned transition after Mr. Valle informed the Management Board
of his intention to retire from the company at the end of 2023.
Bill joined Fresenius Medical Care in 2009. He has been leading the
globally operating Care Delivery segment since 2022. Previously, he
served as CEO for North America
since 2017. He has been a member of the Management Board since
2017. Prior to that, he was Executive Vice President responsible
for the dialysis service business and vascular access business of
Fresenius Medical Care North America from 2014 to 2017. Over the
last decade he was responsible for the transformation of the U.S.
business into a multi-dimensional integrated kidney care
provider.
Craig Cordola is currently
Executive Vice President of Ascension Capital, where he is
responsible for strategic investments. Previously, he was Executive
Vice President and Chief Operating Officer for Ascension. Prior to
joining Ascension in 2017, Mr. Cordola held several senior
executive and leadership positions at Memorial Hermann Health
System in Houston, Texas. He is a
Fellow of the American College of Healthcare Executives and holds a
degree in Psychology from The University of
Texas at Austin. He also earned dual degrees with a Master
of Healthcare Administration (MHA) and a Master of Business
Administration (MBA) from the University of
Houston-Clear Lake.
Michael Sen, Chairman of the
Supervisory Board of Fresenius Medical Care Management AG, said:
"We are delighted to have Craig
Cordola join the Management Board of Fresenius Medical Care
as the leader of the global Care Delivery organization. Craig has a
wealth of knowledge and experience managing large healthcare
systems and organizations. With this expertise, he will be a
crucial player in the Management Board in implementing Fresenius
Medical Care's turnaround and focusing on patient care."
Michael Sen added: "On behalf of the
entire Supervisory Board, I would like to express my sincere
appreciation to Bill for his excellent work over the past years,
his passion for the well-being of patients and his contribution to
the development of Fresenius Medical Care. We wish him all the best
for his retirement."
Helen Giza, CEO and Chair of the
Management Board, said: "Craig joins Fresenius Medical Care with
many years of proven track record of operational management
experience and successfully driving profitable business growth in
different companies in the U.S. healthcare services industry. He
will be a valuable member of my leadership team continuing our
turnaround and transformation while leading Care Delivery into its
next chapter. I would like to thank Bill for his many years of
leadership and remarkable contributions to Fresenius Medical Care
throughout his tenure with us, his passion for our patients and
employees shines through in everything he does. I wish him well in
his retirement."
Craig Cordola said: "I am excited
to join Fresenius Medical Care, the global leader in kidney care
and leading healthcare brand across this industry. I cannot wait to
partner with its leaders – and all of its team members – as we
transform our organization to continue to serve patients and
communities that suffer from renal disease."
Fresenius Medical Care is the world's leading provider of
products and services for individuals with renal diseases of which
around 3.9 million patients worldwide regularly undergo dialysis
treatment. Through its network of 4,050 dialysis clinics, Fresenius
Medical Care provides dialysis treatments for approximately 344,000
patients around the globe. Fresenius Medical Care is also the
leading provider of dialysis products such as dialysis machines or
dialyzers. Fresenius Medical Care is listed on the Frankfurt Stock
Exchange (FME) and on the New York Stock Exchange (FMS).
For more information visit the Company's website at
www.freseniusmedicalcare.com.
Disclaimer:
This release contains forward-looking statements that are
subject to various risks and uncertainties. Actual results could
differ materially from those described in these forward-looking
statements due to various factors, including, but not limited to,
changes in business, economic and competitive conditions, legal
changes, regulatory approvals, impacts related to the COVID-19
pandemic results of clinical studies, foreign exchange rate
fluctuations, uncertainties in litigation or investigative
proceedings, and the availability of financing. These and other
risks and uncertainties are detailed in Fresenius Medical Care AG
& Co. KGaA's reports filed with the U.S. Securities and
Exchange Commission. Fresenius Medical Care AG & Co. KGaA does
not undertake any responsibility to update the forward-looking
statements in this release.
Media
Contact
Leif Heussen
T +49 6172 608-4030
leif.heussen@fresenius.com
Contact for analysts
and investors
Dr. Dominik Heger
T +49 6172 609-2601
dominik.heger@fmc-ag.com
www.freseniusmedicalcare.com
|
View original content to download
multimedia:https://www.prnewswire.com/news-releases/fresenius-medical-care-appoints-craig-cordola-as-new-management-board-member-for-care-delivery-301972839.html
SOURCE Fresenius Medical Care Holdings, Inc.